Zydus Partners Myriad Genetics to Bring Cancer-Risk Assessment Tests to India

Under the agreement, Zydus will introduce the MyRisk Hereditary Cancer Test, MyChoice HRD Plus (Homologous Recombination Deficiency) Test, and the Prolaris Prostate Cancer Prognostic Test across the Indian healthcare ecosystem.

Ahmedabad-based Zydus Lifesciences Ltd has signed an exclusive agreement with US-based Myriad Genetics to introduce cancer-risk assessment and prognostic diagnostic tests in India, expanding access to precision oncology tools for clinicians and patients.

Under the agreement, Zydus will introduce the MyRisk Hereditary Cancer Test, MyChoice HRD Plus (Homologous Recombination Deficiency) Test, and the Prolaris Prostate Cancer Prognostic Test across the Indian healthcare ecosystem. Zydus will be responsible for exclusively marketing the tests, creating awareness, and engaging clinicians nationwide.

According to Zydus Lifesciences Managing Director Sharvil P Patel, the collaboration will focus on enabling access to diagnostic tools that support personalised cancer treatment decisions. He noted that the prostate and ovarian cancer tests provide actionable insights that can help clinicians assess disease progression, guide treatment choices, and streamline clinical workflows. The agreement also includes tests designed to identify hereditary cancer risks in patients and their families.

The diagnostic tests have been widely used across North America, Europe and major global cancer centres. Their introduction in India is expected to provide oncologists with genomic decision-support tools for improved risk assessment and treatment planning.

The MyRisk Hereditary Cancer Test with RiskScore evaluates 63 genes associated with hereditary cancer risk and helps identify genetic changes linked to increased risk across more than 11 cancer types. When combined with family history and other clinical factors, the test provides individualised five-year and lifetime breast cancer risk assessments. It is intended for patients with a personal or family history of cancers such as breast, ovarian, colorectal, pancreatic, and prostate cancer, as well as individuals with known hereditary mutations, including BRCA1 and BRCA2.

The MyChoice HRD Plus Test is a tumour-based test that determines HRD status by analysing genomic alterations, including BRCA mutations and genomic instability. It is used to identify patients with advanced ovarian cancer who may respond to targeted therapies.

The Prolaris Prostate Cancer Prognostic Test is an RNA-based gene expression test that measures tumour aggressiveness and provides a patient-specific risk score. The test assists clinicians in evaluating treatment intensity, suitability for active surveillance, and long-term risk of metastasis and prostate cancer-specific mortality, amid rising prostate cancer incidence in India.

The tests will be made available to patients, clinicians, and healthcare systems as part of Zydus’ diagnostic portfolio in India.

Stay tuned for more such updates on Digital Health News